Diz Reyhan KÜÇÜKKAYA, Meliha NALÇACI, Melih AKTAN, Tanju ATAMER, Deniz SARGIN, Yüksel PEKÇELEN, Kalayoğlu Sevgi BEŞIŞIK, Mesut AYER, Günçay DİNÇOL, Demirel Naciye YILDIRIM, M ustsfs Nuri YENEREL, Akif Selim YAVUZ

Yüz altmış iki kronik idiyopatik trombositopenik purpura olgusunun klinik seyir ve tedavi cevabı yönünden değerlendirilmesi

Amaç: Bu çalışmada 162 erişkin kronik idiyopatik trombositopenik purpura (İTP)'lı hastanın tanı sırasındaki özelliklerini, tedavi endikasyonlarını, klinik seyir ve tedavi sonuçlarını araştırdık. Gereç ve yöntem: 1972-2003 yılları arasında polikliniğimize başvuran ve gözlem altına alınan olgular retrospektif olarak değerlendirildi.Bulgular: Yaşları 12 ile 84 yaş arasında (ortanca: 35 yaş) değişen hastaların 122' si kadın 40' ı erkek idi (K/E: 3,0). Prednizolon (1mg/kg) 138 olguda ilk tedavi seçeneği olarak kullanıldı; 24 olgu tedavisiz olarak takip edildi. Olguların 64'ünde (% 46,3) tam yanıt saptandı. Bu olguların 26'sında PRD dozunun azaltılmasıyla trombositler iki ay içinde tekrar eski haline geriledi. Tam yanıt sağlanan hastaların 11'inde 6 ay ile 4 yıl içinde nüks geliştiği görülmüştür. Tam yanıtın sağlanamadığı olgularda son trombosit değerleri 5.000 ile 125.000/m3 arasında (ortanca: 51.000/m3) bulundu. Ağır trombositopenisi (

Clinical follow-up and treatment response of the 162 patients with chronic idiopathic thrombocytopenic purpura

Aim: In this report, we investigated the presenting clinical features, therapy indications, clinical follow-up and treatment results of the 162 patients with chronic idiopathic thrombocytopenic purpura (ITP). Material and methods: The cases that were followed-up in our outpatient clinic between years 1972 to 2003 were retrospectively analyzed.Results: A hundred and twenty-two of the patients were female, 40 of them were male and their age distribution was between 12 and 84 years (median: 35 years). Prednisolone (1mg/kg) was the first line treatment option in 138 of the patients; 24 of them was followed-up without any treatment. Complete response was achieved in 64 (46,3 %) of the patients. Platelet counts decreased to the beginning level in 26 of the complete responders when the PRD doses were decreased. Eleven of the complete responders showed relapse in between 6 months to 4 years. Platelet counts were found in the range of 5.000/mm3 to 125.000/mm3 in the patients who did not get complete response. There was not any serious bleeding problem other than bruising in none of the patients including those who had severe trombocytopenia. None of our patients died because of bleeding complication during the follow-up period.Conclusion: ITP is an autoimmune disorder characterized by muco-cutaneous bleeding. The pathogenesis of ITP is presumed to be related to platelet destruction via specific auto-antibodies. Bleeding signs and symptoms of the patients with ITP are not always obvious and not as severe as in bone marrow failure syndromes. Cytotoxic agents shouldn't be used if they are not really necessary and the patients' symptoms should be tried to be treated, not the thrombocytopenia itself.

PDF

___

1) Chend Y, Wong RSM, Soo YOY, Chui CH, Lau FY, Chan NPH, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethazone. N Engl J Med 2003; 349:831-836.
2) Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
3) Diz-Küçükkaya R, Gushiken FG, Lopez JA. Thrombocytopenia. In: Lichtman MA (Ed) Williams Hematology New York USA 7th Ed., 2006; pp 1758-1763.
4) George JN, Davidoff F. Idiopathic thrombocytopenic purpura: Lessons from a guideline. Ann Intern Med 1997; 126:317-318.
5) George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331:1207-1211.
6) Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrie I. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
7) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574-596.
8) Imbach P, Kuhne T, Signer E. Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. Br J Haematol 2002; 119:894-900.
9) Kojouri K, George JN. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol 2005; 81:119-125.
10) Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623-2634.
11) Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol 2002; 81:312-319.
12) Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia: A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol 1992; 98:502-510.
13) Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients: An aspect of the myelodysplastic syndrome. Cancer 1989; 64:2506-2510.
14) Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernandez R, Menor D, Rodríguez MJ, Caballero D, Gonzalez R, Mayans J, Millan I and Cabrera JR. On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006; 85:400-406.
15) Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97:2549-2554.
16) Stasi R, Stipa E, Masi M, Cecconi C, Scimò M, Oliva F, Sciarra A, Perrotti A, Adomo G, Amadori S. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98:436-442.
17) Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004; 140:112-120.
18) Wandt H, Frank M Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gäckle R, Geer T, Harms P, Löffler B, Öhl S, Otremba B, Raab M, Schönrock-Nabulsi P, Strobel G, Winter R, Link H. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601-3606.